1. Insights
  2. Blogs
  3. Eye on FDA

FDA Approves the First Flu Vaccine for At Home Use, Providing a Needle Free Option Outside of Traditional Health Care Settings

October 10, 2024

Reading Time : 1 min

By: Nathan A. Brown, Marlee P. Gallant, Caroline D. Kessler, Olive Lee

On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use.

The vaccine, FluMist, is administered by nasal spray and prevents the flu by using a weakened form of live influenza virus strains A and B to create a lasting immune response. FluMist was initially approved by FDA in 2003 for individuals ages 5 to 49, and in 2007, FDA extended the approval of its use to children ages 2 to 5. Until recently, the vaccine could only be administered by medical providers at a doctor’s office or pharmacy. FDA expects that this new option for receiving a flu vaccine with potentially greater convenience and flexibility will increase access.

Under the new approval, FluMist may be self-administered by adults up to 49 years of age or administered by a caregiver for those between ages 2 through 17. A prescription is still required, however, for at‑home use. Beginning next fall, individuals 18 years and older will be able to order FluMist through a third‑party online pharmacy by visiting FluMist’s website and completing an eligibility assessment. If they are eligible, a pharmacist will approve their order, and the vaccine will be shipped to them.

The vaccine is expected to be available for at‑home use for the 2025‑26 flu season.

Share This Insight

Categories

Health CareRegulatoryFood and Drug Administration (FDA)

Previous Entries

Eye on FDA

June 16, 2025

Last week, the U.S. Food and Drug Administration (FDA) released two educational videos and a supplemental fact sheet to guide dietary supplement
manufacturers and distributors through the New Dietary Ingredient Notification (NDIN) review process. Under Section 413 of the Federal Food, Drug, and
Cosmetic Act, manufacturers and distributors must submit an NDIN to notify FDA before marketing a dietary supplement with a new dietary ingredient. These
resources offer guidance on structuring submissions and outline what to expect during the agency’s review. Ultimately, they are intended to enhance the
quality of NDIN submissions and minimize common pitfalls, with the goal of avoiding delays or unfavorable results in the agency’s review....

Read More

Eye on FDA

June 5, 2025

Over the weekend, the Department of Justice (DOJ) did not file an appeal of the U.S. District Court for the Eastern District of Texas’ decision to vacate and set
aside the agency’s final rule on the regulation of laboratory developed tests (LDTs), titled Medical Devices; Laboratory Developed Tests (the LDT Rule). The
LDT Rule would have required laboratories to ensure that their offered LDTs met medical device requirements under a multistage phase out of Food and Drug
Administration’s (FDA) enforcement discretion policy. While the government’s decision not to appeal this ruling may not have been a surprise, questions
remain as to how FDA plans to clarify its policy towards lab test offerings going forward....

Read More

Eye on FDA

June 2, 2025

On May 30, 2025, the Department of Health and Human Services released additional information regarding the Trump administration’s Fiscal Year (FY) 2026
budget request. The release of these FY26 budget materials is timely as Secretary Kennedy and the Food and Drug Commissioner Dr. Makary have started to
testify before Congress on the FY26 budget and the House and Senate Appropriations Committees are moving forward with their annual appropriations work.
Further still, the House Appropriations Committee’s Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies is
scheduled to markup their FY26 Ag-FDA Approps bill later this week....

Read More

Eye on FDA

May 23, 2025

Yesterday, the White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary
Robert F. Kennedy Jr. released its inaugural health report titled, Make Our Children Healthy Again, delivering one of the first widely anticipated deliverables
from the MAHA Commission Executive Order issued earlier this year and noted in our prior alert. The 72-page assessment examines the rising rates of
childhood chronic disease in the country—including obesity, heart disease and diabetes—and explores potential contributing factors. Specifically, the report
identifies and focuses on four potential drivers:...

Read More

Eye on FDA

May 12, 2025

On May 9, 2025, the U.S. Food and Drug Administration (FDA) granted three color additive petitions, approving two new colorings and expanding one existing
approval. These approvals come after the agency’s announcement last month to phase out all petroleum-based synthetic dyes in food by the end of 2026
and transition to natural alternatives (see our post here). Under section 721 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), color additives (unless
exempt from batch certification) are subject to FDA approval to determine their safety for use in food. The agency evaluates the safety of color additives
based on multiple factors including projected human dietary exposure to the additive, toxicological data, and other relevant information. Once FDA approves
a color additive petition, any manufacturer can use the additive in foods for the approved intended uses....

Read More

Eye on FDA

May 8, 2025

In the last two weeks, the Department of Health and Human Services (HHS) has filled key artificial intelligence (AI) positions at HHS and the U.S. Food and
Drug Administration (FDA). These appointments, as well as recent statements from HHS and FDA leadership, align with the Trump administration’s intention
to use AI to improve regulatory efficiency at HHS and beyond....

Read More

Eye on FDA

April 23, 2025

This week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS), announced a series of
new measures to phase out all petroleum-based synthetic dyes in food by the end of 2026. This initiative is part of the broader “Make America Healthy Again”
(MAHA) agenda aimed at bolstering food safety. Citing growing concerns about the potential role of petroleum-based food dyes in childhood diabetes,
obesity, depression and attention-deficit/hyperactivity disorder (ADHD), the agency plans to establish a national standard and timeline for the food industry to
transition to natural alternatives....

Read More

Eye on FDA

April 16, 2025

On April 10, 2025, the Food and Drug Administration (FDA) announced its plan to replace animal testing in the development of monoclonal antibody therapies
and other drugs in one of the first announcements by the agency since Commissioner Makary was confirmed to lead it. In its announcement, FDA highlighted
that this more modern approach is designed to improve drug safety and accelerate the evaluation process, while also reducing animal experimentation,
lowering research and development costs, and lowering drug prices....

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.